NasdaqGM:LGNDPharmaceuticals
Assessing Ligand Pharmaceuticals (LGND) Valuation After Strong One Year Returns And Elevated P/E Ratio
Event context and recent share performance
Ligand Pharmaceuticals (LGND) has been drawing attention after a period of mixed share performance, with a roughly 0.3% gain over the past month and a 3.5% decline over the past 3 months.
For investors tracking the name, the recent 1 day move of about 2.5% and 1 week return of roughly 5.3% sit alongside a 1 year total return near 70%, all against a last close of US$196.17.
See our latest analysis for Ligand Pharmaceuticals.
The recent 2.5% 1 day...